The central scientific distinction is combustion. Conventional cigarettes burn tobacco at high temperatures, generating smoke containing thousands of chemical compounds, including carbon monoxide, fine particulate matter, and numerous carcinogens. E-cigarettes do not burn tobacco. Instead, an electrically heated element vaporizes a liquid that commonly contains nicotine, solvents such as propylene glycol and vegetable glycerin, and flavoring chemicals. The resulting aerosol is not harmless, but its chemical composition and toxicant profile differ substantially from those of cigarette smoke. This difference forms the foundation of the harm-reduction argument surrounding adult smokers who cannot or do not want to quit nicotine immediately.

The article’s recommendations are expected to focus on clinical decision-making rather than presenting e-cigarettes as risk-free consumer products. Nicotine is highly addictive and can affect cardiovascular function, while inhaled aerosol may contain irritants, ultrafine particles, metals released from device components, and other substances whose long-term effects continue to be studied. Device design, liquid formulation, heating temperature, and user behavior can all influence exposure. For that reason, a clinician’s role is not simply to recommend or reject vaping, but to assess the individual’s smoking history, previous quit attempts, dependence, medical conditions, and likelihood of switching completely away from combustible tobacco.

Evidence supporting e-cigarettes for cessation has generally examined whether smokers are more likely to stop using cigarettes when given access to vaping products, often alongside behavioral support. In this context, the relevant clinical outcome is not whether a person becomes nicotine-free immediately, but whether they discontinue cigarette smoking and maintain abstinence over time. The recommendations emphasize that a complete transition away from combustible cigarettes is critical. Continuing to smoke while also vaping, a pattern known as dual use, may limit potential health benefits because exposure to cigarette smoke persists.

Pharmacologic treatment for smoking cessation traditionally includes nicotine replacement therapy, varenicline, and bupropion, depending on a patient’s health profile and preferences. These therapies work through different mechanisms. Nicotine patches, gum, lozenges, inhalers, and nasal sprays provide controlled nicotine doses without tobacco combustion. Varenicline partially stimulates nicotine receptors in the brain while reducing the rewarding effects of smoking, and bupropion alters neurotransmitter activity associated with craving and withdrawal. E-cigarettes also deliver nicotine, but they can reproduce behavioral and sensory elements of smoking, including hand-to-mouth movement and inhalation, which may help some smokers manage conditioned habits.

The clinical guidance is therefore likely to treat e-cigarettes as one possible cessation tool within shared decision-making. A patient who has repeatedly failed to quit with approved medications, or who strongly prefers an inhaled nicotine product, may benefit from a carefully monitored attempt to switch completely from cigarettes to e-cigarettes. Clinicians may need to explain nicotine concentrations, product variability, dependence risks, and the importance of setting a plan to reduce or eventually stop vaping. Counseling should also distinguish adult smoking cessation from youth prevention, because nicotine exposure is particularly concerning for adolescents, pregnant people, and individuals who do not already smoke.

The recommendations arrive amid continuing scientific debate over how to communicate the relative risks of vaping. Public health messages must navigate two hazards at once: overstating the dangers of e-cigarettes may discourage smokers from switching, while understating them may encourage non-smokers, especially young people, to begin using nicotine. Relative-risk communication is technically difficult because the comparison is not between vaping and clean air alone. For an adult who otherwise would continue smoking, replacing cigarettes with regulated nicotine aerosol may reduce exposure to combustion-related toxicants. For a non-smoker, beginning to vape introduces avoidable exposure and the possibility of addiction.

Leavens and colleagues also highlight the need for clinicians to discuss evidence quality and uncertainty. Research on cessation outcomes has produced meaningful support for e-cigarettes, but products differ widely and long-term epidemiologic data remain less extensive than the evidence base for cigarette-related disease. Outcomes can be affected by product access, nicotine delivery, adherence, counseling intensity, and whether participants use e-cigarettes exclusively or alongside cigarettes. A scientifically responsible recommendation must therefore separate established findings from unresolved questions, monitor emerging safety data, and avoid treating all vaping products as biologically identical.

For patients, the practical message is that quitting cigarettes remains the primary goal, and evidence-based support should be individualized. People who choose e-cigarettes as a cessation aid should be encouraged to stop smoking completely, receive behavioral counseling, and maintain follow-up with a health professional. Clinicians can reassess cravings, withdrawal symptoms, nicotine intake, respiratory complaints, and progress toward cigarette abstinence. If vaping does not help a patient quit, other medications or combinations of treatments may be appropriate. The broader objective is to move people away from the most dangerous form of nicotine use: inhaling smoke produced by burning tobacco.

By placing e-cigarettes within the broader framework of smoking-cessation pharmacology, the JAMA article seeks to bring clinical practice into closer alignment with the evidence surrounding nicotine delivery and tobacco-related harm. Its approach does not eliminate the controversies surrounding vaping, nor does it declare electronic devices safe. Instead, it recognizes a harm-reduction reality: for adults who smoke, the health consequences of continued combustion exposure are severe, and some may be more likely to quit cigarettes with an e-cigarette than with other available options. The challenge for medicine is to use that potential strategically while preventing new nicotine addiction and ensuring that complete cigarette cessation remains the destination.

Subject of Research: Clinical recommendations on the use of e-cigarettes as a smoking-cessation intervention and their role in evidence-based pharmacologic treatment.

Web References: https://doi.org/10.1001/jama.2026.13087

References: Leavens, Eleanor L. S., et al. Article published in JAMA. DOI: 10.1001/jama.2026.13087.

Keywords: E-cigarettes, electronic cigarettes, smoking cessation, nicotine, tobacco harm reduction, pharmacologic treatment, cigarette smoking, clinical guidance, aerosol exposure, dual use, combustion products, public health

The recent proliferation of electronic cigarettes has added a layer of complexity to the substance abuse landscape. Despite being marketed as less harmful alternatives to traditional cigarettes, e-cigarettes often contain nicotine levels that can be several times higher than regular tobacco products. In Brazil, where e-cigarettes are banned, the absence of regulatory control has led to a chaotic market filled with unregulated liquids that frequently incorporate dangerous substances. Research indicates that some e-liquids contain up to 100 times the nicotine concentration of conventional cigarettes, underscoring the potential for rapid addiction and extreme health complications.

Among the additives found in these unregulated e-liquids, vitamin E acetate has been particularly problematic. Linked to severe lung injuries and even fatalities in the United States, this substance highlights the need for effective monitoring of what is being consumed. Luciano Arantes, a prominent researcher at the Brazilian National Institute of Science and Technology on Psychoactive Substances, remarked upon the cruel irony of e-cigarette marketing strategies that promise safety while packaging dangerously potent substances.

Furthermore, the rise of synthetic cannabinoids—laboratory-created compounds designed to simulate THC, the psychoactive element in cannabis—presents an urgent public health issue. These synthetic drugs are known to be significantly more potent than their natural counterparts, with the potential to cause severe neurological reactions including seizures and psychotic episodes. Arantes warns about the so-called “chemical race” among clandestine groups, as they continue to create newer and more potent variants of these substances, complicating identification and treatment protocols for health professionals and users alike.

The newly developed sensor, detailed in the prominent journal “Talanta,” employs an electrochemical detection method to identify synthetic cannabinoids with remarkable precision. Larissa Magalhães de Almeida Melo, an academic and principal investigator on the project, emphasized that the sensor is designed for use in diverse environments. By creating a device that can deliver high selectivity and sensitivity, the researchers have provided a formidable tool to combat the unknown and dangerous landscape of synthetic drugs.

One of the most compelling features of the sensor lies in its user-friendly design. Built around a boron-doped diamond electrode, which boasts high stability and durability, it connects seamlessly to personal devices like smartphones through USB-C or Bluetooth. The electrochemical responses are displayed in a current-voltage graph format, allowing for straightforward interpretation of the data. The ability to analyze samples with minimal infrastructure makes this device especially beneficial in emergency scenarios.

In initial testing, the sensor successfully detected traces of AB-Chminaca and MDMB-4en-Pinaca, two notorious synthetic cannabinoids, with sensitivity down to concentrations as low as 0.2 µM. This impressive level of detection is particularly noteworthy given that the samples were often laden with high levels of nicotine and other substances, proving the sensor’s robustness in complex mixtures.

As the research progresses, the implications for public health are profound. Not only does the device serve as a screening tool for law enforcement agencies, but it also has applications in emergency medical settings and harm reduction initiatives. The researchers are actively collaborating with the BACO Project, which investigates new psychoactive substances in party environments, to extend the sensor’s capabilities beyond detection. The goal is to provide users with immediate access to information about the substances they intend to consume, aiming to reduce harm and prevent overdose.

Arantes highlighted the significant gap in user awareness, with surveys indicating that a staggering 63% of drug users are unaware of what they are actually consuming. By leveraging this sensor technology to promote transparency, the team hopes to equip users with the information necessary to make informed decisions about their health, potentially saving lives in the process.

The adaptability of the sensor technology is an additional key strength emphasized by the researchers. They are also working on developing sensors for various other substance classes, including LSD and synthetic cathinones. With plans to incorporate colorimetric reagents to enhance visual results, the potential applications for this type of technology are continuously expanding.

While scientific innovation is paving the way for better detection and understanding of psychoactive substances, it is crucial to remember that education and regulation must evolve at a similar pace. The effort to help users understand the risks associated with new synthetic variants is as essential as the technology itself. Only through collaborative efforts can society mobilize effectively against the challenges posed by these emerging drugs.

This ongoing research is backed by the São Paulo Research Foundation (FAPESP), which is committed to fostering scientific inquiry throughout Brazil. Continued support and collaboration are paramount for addressing the challenges posed by synthetic drugs and their effects on public health. With the new sensor in the hands of users and professionals alike, the hope is that harm can be mitigated, and informed decisions facilitated.

As the landscape of synthetic drug usage evolves rapidly, the importance of timely and accurate detection cannot be overstated. The intersection of science and public health represented by this sensor technology is a promising development in the battle against substance abuse, ensuring that individuals are empowered to prioritize their health and wellbeing above all else.

Subject of Research: Portable sensor technology for detecting synthetic cannabinoids in e-cigarettes and biological samples.
Article Title: A novel electrochemical method for detecting synthetic cannabinoids in e-cigarette and biological samples using a lab-made electrode.
News Publication Date: 14-Jul-2025
Web References: www.fapesp.br/en, www.agencia.fapesp.br/en
References: “Talanta,” DOI 10.1016/j.talanta.2025.128574
Image Credits: Larissa Melo/INCT-SP

Keywords: Synthetic cannabinoids, electrochemical sensor, e-cigarettes, public health, drug detection, harm reduction, toxicity, psychoactive substances, portable devices, Brazil.